2018 update of the APLAR recommendations for treatment of rheumatoid arthritis-Reference-Cited by-同舟云学术

2018 update of the APLAR recommendations for treatment of rheumatoid arthritis

Published:2019-02-27 Issue:3 Volume:22 Page:357-375
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Lau Chak Sing¹^ORCID,Chia Faith²,Dans Leonila³⁴,Harrison Andrew⁵^ORCID,Hsieh Tsu Yi⁶,Jain Rahul⁷,Jung Seung Min⁸^ORCID,Kishimoto Mitsumasa⁹,Kumar Ashok¹⁰,Leong Khai Pang²,Li Zhanguo¹¹,Lichauco Juan Javier¹²,Louthrenoo Worawit¹³^ORCID,Luo Shue Fen¹⁴,Mu Rong¹¹,Nash Peter¹⁵,Ng Chin Teck¹⁶¹⁷^ORCID,Suryana Bagus¹⁸,Wijaya Linda Kurniaty¹⁹,Yeap Swan Sim²⁰

Affiliation:

1. Division of Rheumatology and Clinical Immunology, Department of Medicine The University of Hong Kong Pokfulam Hong Kong

2. Department of Rheumatology, Allergy and Immunology Tan Tock Seng Hospital Singapore Singapore

3. Department of Pediatrics University of the Philippines Manila Manila Philippines

4. Department of Clinical Epidemiology University of the Philippines Manila Manila Philippines

5. Department of Medicine University of Otago Wellington Wellington New Zealand

6. Division of Allergy, Immunology and Rheumatology Taichung Veterans General Hospital Taichung Taiwan

7. Jaipur Arthritis Centre Jaipur India

8. Division of Rheumatology, Department of Internal Medicine Yonsei University College of Medicine Seoul Korea

9. Immuno‐Rheumatology Center St Luke's International Hospital, St Luke's International University Tokyo Japan

10. Department of Rheumatology Fortis Flt. Lt. Rajan Dhall Hospital New Delhi India

11. Department of Rheumatology and Immunology Beijing University People's Hospital Beijing China

12. Rheumatology, Allergy and Immunology Center St. Luke's Medical Center Quezon City Philippines

13. Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine Chiang Mai University Chiang Mai Thailand

14. Department of Rheumatology, Allergy, Immunology Chang Gung Memorial Hospital Taipei Taiwan

15. Department of Medicine, Faculty of Medicine University of Queensland Brisbane Queensland Australia

16. Department of Rheumatology and Immunology Singapore General Hospital Singapore Singapore

17. Duke‐NUS Medical School Singapore Singapore

18. Department of Internal Medicine, Faculty of Medicine Brawijaya University Malang Indonesia

19. Sari Asih Ciputat Hospital South Tangerang Indonesia

20. Department of Medicine Subang Jaya Medical Centre Subang Jaya Malaysia

Funder

Asia Pacific League of Associations for Rheumatology

Publisher

Wiley

Subject

Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1756-185X.13513

Reference175 articles.

1. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study;Cross M;Ann Rheum Dis,2014

2. Prevalence of rheumatoid arthritis in low‐ and middle‐income countries: a systematic review and analysis;Rudan I;J Glob Health,2015

3. Treatment with Biologicals in Rheumatoid Arthritis: An Overview

4. Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases

5. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis;Hodge JA;Clin Exp Rheumatol,2016

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics and prevalence of clinical remission of rheumatoid arthritis in a nationwide study from Indonesia;International Journal of Rheumatic Diseases;2024-02

2. Lipid mediators obtained from docosahexaenoic acid by soybean lipoxygenase attenuate RANKL-induced osteoclast differentiation and rheumatoid arthritis;Biomedicine & Pharmacotherapy;2024-02

3. Delayed low-dose methotrexate excretion in a rheumatoid arthritis patient: A case report and literature review;Medicine;2024-01-26

4. Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis;RMD Open;2024-01

5. Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study;The Lancet Regional Health - Western Pacific;2024-01